Replies to post #173521 on Biotech Values

[anesthesia doc]

Enanta Pharmaceuticals Announces Results from Four All-Oral, Interferon-Free, Phase 3 Studies for the Treatment of Genotype 1 Hepatitis C Virus Infection

http://finance.yahoo.com/news/enanta-pharmaceuticals-announces-results-four-124400458.html

Enanta Pharmaceuticals Announces Results from Four All-Oral, Interferon-Free, Phase 3 Studies for the Treatment of Genotype 1 Hepatitis C Virus Infection
Results confirm previously reported data in genotype 1 (GT1) patient populations demonstrating high sustained virologic response rates at 12 weeks post-treatment (SVR12)
Results demonstrate SVR12 of 97 to 100% in GT1b patients
SVR12 of 92 to 96% was shown in the difficult-to-treat GT1 cirrhotic patient population
AbbVie announced it expects U.S. launch in 2014